PT  - JOURNAL ARTICLE
AU  - Preethi Ramachandran
AU  - Mahesh Gajendran
AU  - Abhilash Perisetti
AU  - Karim Osama Elkholy
AU  - Abhishek Chakraborti
AU  - Giuseppe Lippi
AU  - Hemant Goyal
TI  - Red blood cell distribution width (RDW) in Hospitalized COVID-19 Patients
AID  - 10.1101/2020.06.29.20143081
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20143081
4099  - http://medrxiv.org/content/early/2020/07/03/2020.06.29.20143081.short
4100  - http://medrxiv.org/content/early/2020/07/03/2020.06.29.20143081.full
AB  - Introduction Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is causing dramatic morbidity and mortality worldwide. The Red Blood Cell Distribution Width (RDW) has been strongly associated with increased morbidity and mortality in multiple diseases.Objective To assess if elevated RDW is associated with unfavorable outcomes in hospitalized COVID-19.Methods We retrospectively studied clinical outcomes of hospitalized COVID-19 patients for their RDW values. In-hospital mortality was defined as primary outcome, while septic shock, need for mechanical ventilation, and length of stay (LOS) were secondary outcomes.Results A total of 294 COVID-19 patients were finally studied. Overall prevalence of increased RDW was 49.7% (146/294). RDW was associated with increased risk of in-hospital mortality (aOR, 4.5; 95%CI, 1.4-14.3) and septic shock (aOR, 4.6; 95%CI, 1.4-15.1) after adjusting for anemia, ferritin, and lactate. The association remained unchanged even after adjusting for other clinical confounders such as age, sex, body mass index, coronary artery disease, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. No association was found instead with mechanical ventilation and median LOS.Conclusion Elevated RDW in hospitalized COVID-19 patients is associated with a significantly increased risk of mortality and septic shock.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by institutional IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymous data can be arranged if needed